Wogonin can delay the progression of ventricular hypertrophy and remodeling by specifically targeting Nrf-2 and promoting the expression of downstream antioxidant genes HO-1 and NQO-1 [11]. The gene discussed is NQO1; the disease is Ventricular hypertrophy.